Result of AGM and voting results

Ondine Biomedical Inc.

30 June 2026

 

30 June 2026

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine", or "the Company")

Result of AGM and voting results

Ondine Biomedical (AIM: OBI) announces that all resolutions set out in the Notice of AGM dated 4 June 2026 were duly passed at its Annual General Meeting ("AGM") held on 30 June 2026.

The voting results of the AGM were as follows:

	In Favor		Against		Withheld
Resolution	Votes	%	Votes	%	Votes	%
1. Election of Directors
Carolyn Cross	314,158,038	100.00	0	0.00	0	0.00
Nicolas G. Loebel	314,158,038	100.00	0	0.00	0	0.00
Jean Charest	261,714,535	83.31	0	0.00	52,443,503	16.69
Jean Duvall	261,714,535	83.31	0	0.00	52,443,503	16.69
Junaid Bajwa	261,714,535	83.31	0	0.00	52,443,503	16.69
Margaret Shaw	261,714,535	83.31	0	0.00	52,443,503	16.69
2. Appointment of Auditors	311,758,038	99.24	0	0.00	2,400,000	0.76

 

 

Enquiries:

Ondine Biomedical Inc.	www.ondinebio.com
Carolyn Cross, CEO	[phone]
Strand Hanson Limited (Nominated & Joint Financial Adviser)
James Harris, Richard Johnson, Imogen Ellis	[phone]
Peel Hunt LLP (Broker & Joint Financial Adviser)
James Steel, Dr. Chris Golden	[phone]
5654 & Company (Financial PR and IR Adviser)	[e-mail]
Matthew Neal, Chris Gardner, Melissa Gardiner	[phone] [phone]

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company focused on the development of light-activated antimicrobial therapies ('photodisinfection') for the prevention and treatment of infections, including those associated with multidrug-resistant organisms.

Ondine's lead product, Steriwave^®, is authorized for nasal decolonisation in Canada and certain international markets. In the United States, the technology has been granted Qualified Infectious Disease Product designation and Fast Track status by the U.S. Food and Drug Administration and recently completed enrolment in its Phase 3 clinical trial.

The Company has a pipeline of additional photodisinfection products in various stages of development for application in areas including chronic sinusitis, ventilator-associated pneumonia, burns and other indications.

 

END